Clinical Trial Detail

NCT ID NCT03057795
Title Nivolumab and Brentuximab Vedotin After Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Classical Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors City of Hope Medical Center
Indications

Hodgkin's lymphoma

Therapies

Brentuximab vedotin + Nivolumab

Age Groups: adult senior

No variant requirements are available.